{
    "nct_id": "NCT04628338",
    "official_title": "A Pilot Study of IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation",
    "inclusion_criteria": "* Recipients of allogeneic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome from a human leukocyte antigen (HLA) matched donor\n* Relapsed of primary disease with 5% to 20% of blasts in the bone marrow by flow cytometry in the bone marrow with an clear leukemia-associated immunophenotype (If the patient received therapy to treat the relapse, he or she must have 5-20% residual blasts prior to enrollment on this study)\n* Performance status KPS score >60% (ECOG 0-2)\n* No increases in systemic immunosuppression in the prior four weeks other than to maintain therapeutic levels\n* No systemic corticosteroid with a dose higher than 0.5mg/kg/day prednisone or equivalent\n* No history of grade IV acute GVHD\n* No new systemic immunosuppressive medications in the prior two weeks initiated due to GVHD\n* Willingness to have bone marrow and peripheral blood collected as per the study protocol\n* Must be able to give informed consent\n* Age 18 or older\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Contraindication to receive IFN-γ including known hypersensitivity to interferon-gamma, E. coli derived products or any component of the product\n* Subjects with a positive pregnancy test or who are breastfeeding\n* For men or women of childing bearing potential (age < 50 without hysterectomy or oophorectomy or documented menopause), unwilling to use effective contraception for the duration of the study.\n* Primary engraftment failure\n* Active cardiac arrhythmias not controlled by medical management or current NYHA class II or higher congestive heart failure\n* Active ischemic heart disease not well controlled with medications\n* A seizure disorder not well controlled by medications\n* Estimated GFR <30 mL/min\n* AST/SGOT or ALT/SPOT > 5 x ULN\n* Total bilirubin > 3 x ULN\n* Chemotherapy (other than hypomethylating and/or venetoclax therapy) within the prior 4 weeks\n* Body surface area at or less than 1.5 m2, or greater than 2.5 m2 so as to minimize the variation in IFN-γ exposure based on differences in BSA.\n* Patients less than 18 years old.\n* Pregnant or breastfeeding patients.",
    "miscellaneous_criteria": ""
}